

# United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/690,844	10/23/2003	Bishwagit Nag	121633-40306509	5401
43569	43569 7590 04/28/2005		EXAMINER	
MAYER, BROWN, ROWE & MAW LLP 1909 K STREET, N.W.			BARTS, SAMUEL A	
	DN, DC 20006		ART UNIT	. PAPER NUMBER
	,		1621	
		DATE MAILED: 04/28/2005		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		10/690,844	NAG ET AL.			
		Examiner	Art Unit			
		Samuel A. Barts	1621			
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply sepecified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1)⊠	Responsive to communication(s) filed on 14 De	ecember 2004.				
2a)□	This action is FINAL. 2b)⊠ This action is non-final.					
3)□						
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Dispositi	on of Claims					
4)⊠	4)⊠ Claim(s) <u>1,2,4-7,9,10,14-18 and 24-34</u> is/are pending in the application.					
	4a) Of the above claim(s) <u>1,2,4-7,9,10,14-18,25,28,29 and 34</u> is/are withdrawn from consideration.					
5)□	5) Claim(s) is/are allowed.					
6)⊠	Claim(s) 24-27 and 30-33 is/are rejected.					
7)	Claim(s) is/are objected to.					
8)□	Claim(s) are subject to restriction and/or	election requirement.	• .			
Applicati	on Papers					
9)□ .	The specification is objected to by the Examiner	•	·			
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority u	nder 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
Attachment	(s)					
1) Notice	of References Cited (PTO-892)	4) Interview Summary (	PTO-413)			
3) 🛛 Inform	e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) No(s)/Mail Date	Paper No(s)/Mail Dat 5) Notice of Informal Pa 6) Other:				
S Patent and To	adamark Office		•			

Application/Control Number: 10/690,844

Art Unit: 1621

#### **DETAILED ACTION**

#### Election/Restrictions

1. Applicant's election without traverse of the species 3-(3,5-dimethoxypheynyl)-2(4-hydroxypheynyl)-acrylic acid methyl ester in the reply filed on 12/14/2004 is acknowledged. Claims 24, 26, 27 and 30-33 read on this species.

### **Double Patenting**

2. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

3. Claims 24, 26, 27 and 30-33 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-5 and 11-18 of U.S. Patent No. 6,626,197.

An obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but an examined application claim is not patentably distinct from the reference claim(s) because the examined claim is ether anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428,46 USPQ2d 1226 (fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985)

Although the conflicting claims are not identical, they are not patentably distinct from each other because the elected species which is embraced by the instant claims is an obvious variant of the compound of the US patent. The patented claims are drawn to the acid and pharmaceutical acceptable

Art Unit: 1621

salt of 3-(3,5-dimethoxypheynyl)-2(4-hydroxypheynyl)-propenoate. In particular, the sodium salt is preferred. The simply esters of an acid pharmaceutical compound are obvious because they are well-known prodrugs for the acid compound. The use of esters is a well-known route to administer the acid compound. The ester compounds are converted to the acid compounds when taken orally.

## Claim Rejections - 35 USC § 102

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 5. Claims 24, 26, 27 and 30-33 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Jacobson et al (J. Org. Chem. Vol. 44, No. 22, 1979 pages 4013-4014).

  Jacobson et al disclosed the following compound:

The compound anticipates the claims when  $R_1=R_2=R_5=C_1-C_{20}$  alkoxy,  $R_4=OH$ ,  $R_3=H$  and  $R_6=linear$  alkyl which is optionally substituted. Please note the compound itself reads on the pharmaceutical composition claims.

Art Unit: 1621

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Samuel A. Barts whose telephone number is 571-272-2870. The examiner can normally be reached on 6:30-3:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor,

Johann Richter can be reached on 571-272-0646. The fax phone number for the organization where this

application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application
Information Retrieval (PAIR) system. Status information for published applications may be obtained
from either Private PAIR or Public PAIR. Status information for unpublished applications is available
through Private PAIR only. For more information about the PAIR system, see http://pairdirect.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic
Business Center (EBC) at 866-217-9197 (toll-free).

Samuel A Barts Primary Examiner Art Unit 1621